Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3075% below fair value

$8.07−0.17 (-2.00%)

Close on Nov 13, 2026Market cap $46.69MP/E –Yield –

Xilio Therapeutics statistics

69 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Mar 22, 2027 (estimated, before the open)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $46.69M; $272.32M
Enterprise Value: -$75.49M; $146.23M
PS Ratio: 0.85; 3.66
PB Ratio: 0.68; 2.00
P/TBV Ratio: 0.68; 2.22

Enterprise valuationIndustry

EV / Sales: -1.37; 2.57

Share statisticsIndustry

Shares Outstanding: 6M; 58M
Shares Change (YoY): 144.3%; 10.8%
Shares Change (QoQ): 0.12%; 0.50%
Shares Held by Institutions: 58.9%; 56.4%

Short sellingIndustry

Short Interest: 382,761; –
Short Interest Change: -4.39%; -0.80%
Short % of Shares Outstanding: 6.62%; 6.30%
Days to Cover: 20.30; 5.15

Stock price statisticsIndustry

52-Week High: $11.30; –
52-Week Low: $6.47; –
20-Day Moving Average: $8.24; –
50-Day Moving Average: $8.69; –
200-Day Moving Average: $8.48; –
Average True Range (14): $0.57; –
Price Change (1 Week): -6.32%; -1.15%
Price Change (1 Month): -10.5%; -4.87%
Price Change (3 Months): -14.9%; -21.0%
Price Change (6 Months): -3.41%; -20.6%
Price Change (YTD): -9.90%; -23.6%
Price Change (1 Year): -25.4%; -22.4%
Price Change (3 Years): -56.0%; -29.5%
Price Change (5 Years): -97.4%; -77.9%
Average Volume (10 Days): 11,112; –
Average Volume (20 Days): 14,635; –
Average Volume (90 Days): 17,752; –
Relative Volume: 0.42; 0.70
Relative Strength Index (14): 43.3; 43.4
Volatility (1 Year): 46.0%; 80.1%
Beta (5 Years): 0.89; 1.07

MarginsIndustry

Operating Margin: -74.9%; -38.7%
Profit Margin: -20.9%; -31.6%
EBITDA Margin: -72.5%; -27.7%
FCF Margin: -104.8%; -9.56%

Returns on capitalIndustry

Return on Equity (ROE): -38.2%; -49.9%
Return on Assets (ROA): -8.56%; -40.6%
Return on Capital Employed (ROCE): -38.1%; -37.9%

Financial positionIndustry

Current Ratio: 4.72; 3.30
Quick Ratio: 4.56; 2.39

GrowthIndustry

Revenue Growth (YoY): 73.0%; 6.82%

EfficiencyIndustry

Asset Turnover: 0.41; 0.40
Revenue Per Employee: $723.82K; $429.29K
Profits Per Employee: -$151.18K; -$689.41K
Employee Count: 76; 74
WACC: 9.57%; 10.2%

Income statement (TTM)Industry

Revenue: $55.01M; $66.37M
Operating Income: -$41.19M; -$21.37M
Net Income: -$11.49M; -$22.35M
EBITDA: -$39.87M; -$17.21M

Balance sheetIndustry

Cash & Short-Term Investments: $122.18M; $68.68M
Net Cash (Debt): $122.18M; $17.76M
Net Cash Per Share: $21.13; $0.80
Equity (Book Value): $68.23M; $53.89M
Book Value Per Share: $11.80; $1.50
Tangible Book Value: $68.23M; $27.13M
Working Capital: $99.70M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$56.90M; -$12.38M
Capital Expenditures: -$728.00K; -$1.00M
Free Cash Flow: -$57.63M; -$18.21M
FCF Per Share: -$9.97; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -24.6%; -21.8%
FCF Yield: -123.4%; -9.44%

Scores and fair valueIndustry

Altman Z-Score: -3.87; 0.23
Piotroski F-Score: 5; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	XLO	S&P 500	Difference	XLO per year	S&P 500 per year
1 month	-12.4%	-3.0%	−9.4 pts
3 months	-10.4%	-2.8%	−7.6 pts
Year to date	-9.9%	+11.5%	−21.4 pts
1 year	-17.8%	+13.5%	−31.2 pts
3 years	-59.1%	+77.7%	−136.8 pts	-25.8%	+21.1%
5 years	-97.4%	+72.6%	−170.0 pts	-51.8%	+11.5%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M XLO shares were sold short on Oct 30, 2026, down 4.4% from the previous report. At recent volumes it would take 20.3 days to buy them back. Over the last 20 sessions, 38.1% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	382,761	-4.4%	18,852	20.3
Oct 15, 2026	400,316	-2.4%	9,727	41.2
Sep 30, 2026	410,050	-0.7%	9,210	44.5
Sep 15, 2026	412,963	-1.3%	11,055	37.4
Aug 31, 2026	418,277	-0.9%	10,705	39.1
Aug 14, 2026	421,921	-0.9%	13,340	31.6
Jul 31, 2026	425,882	+58.8%	34,680	12.3
Jul 15, 2026	268,180	+53.6%	59,349	4.5
Jun 30, 2026	174,619	+0.7%	47,868	3.6
Jun 15, 2026	173,470	+5.0%	24,458	7.1
May 29, 2026	165,274	-3.6%	30,465	5.4
May 15, 2026	171,370	+5.2%	95,033	1.8

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Xilio Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-14 reverse split on Mar 16, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is XLO.

Compare: XLO vs TNGX · XLO vs NKTR · XLO vs PRLD · XLO vs ENTA · XLO vs XNCR

Revenue growth73.0% · median -5.2%

Operating margin-74.9% · median -171.8%

Net margin-20.9% · median -183.3%

Company	Revenue	Growth
XNCR	$200.49M	+33.5%
ENTA	$65.26M	–
NKTR	$55.23M	-43.9%
XLO	$55.01M	+73.0%
PRLD	$22.42M	+220.3%
TNGX	$0	-100.0%

Company

Next earnings (est.): Mar 22, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 76
Held by institutions: 58.9%
Auditor: Ernst & Young LLP
SEC CIK: 1840233

Advertisement
300 × 250

See a number that looks wrong?